GBL is metabolised in the body to Gamma-hydroxybutyrate (GHB), which is commonly used as a ‘date-rape’ drug. This legislation is due to come into force in June 2022.
This classification change will mean that any organisations using GBL within their products will require a licence from the Home Office in order for it to be accessed and used.
BIVDA is aware that GBL is used within the IVD supply chain, notably in labelling inks, in diabetes care, and other solvent-based processes. It was introduced as an eco-friendly alternative to acetone.
In order to ensure the scope of this regulatory change is understood by the Home Office, BIVDA intends to write on behalf of our membership. In order to do this, we need to understand the impact this will have on the sector, and if you are aware of any alternatives.
Please compete this survey to provide us with this information.
If there is anything further you wish to be included, or you think is important for us to be aware of, please contact Ashleigh as soon as possible.